Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest liver cancer Stories

2014-04-17 15:40:57

Deaths from viral Hepatitis B and C have surpassed HIV/AIDS in many countries, including Australia and in Western Europe, according to an analysis of the 2010 Global Burden of Disease study. The analysis was conducted by Dr Benjamin Cowie and Ms Jennifer MacLachlan from the University of Melbourne and Melbourne Health, and was presented at The International Liver Congress in London earlier this month. “Liver cancer is the fastest increasing cause of cancer deaths in Australia,...

2014-04-14 12:33:30

Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focused on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC). "Human hepatocellular carcinoma is one of the most prevalent cancers worldwide and the second most frequent cause of cancer-related death," said EASL's Scientific Committee Member Dr Helen Reeves Senior Lecturer & Honorary Consultant...

Hepatitis C Treatment Without The Side Effects Of Interferon
2014-04-14 10:21:29

redOrbit Staff & Wire Reports - Your Universe Online A new orally-administered antiviral therapy has reportedly cured hepatitis C infection in over 90 percent of patients with liver cirrhosis, according to research published Saturday in the New England Journal of Medicine. Previously, the only treatment method that showed effectiveness against hepatitis C was interferon. However, patients treated with this agent often suffered relapses and experienced multiple adverse side effects....

2014-04-11 13:01:17

Significant new data presented today at the International Liver Congress™ 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy. This new therapeutic approach in the treatment of HCC could be very important as without treatment the 5 year survival rate is just 5%. Globally, HCC accounts for 746,000 deaths, and in the UK alone is responsible for over 4,000 deaths per year. Glypican-3 (GPC3) is a tumor associated antigen expressed in...

2014-04-09 23:29:35

Cancers of the liver are increasing in incidence faster than any other cancer in the U.S. and other western countries, and are a leading cause of cancer death worldwide. CanLiv - The Hepatobiliary Cancers Foundation will bring together researchers, cancer doctors, patient advocates, and industry partners to collaboratively develop better treatment for liver cancer patients at its 4th Annual Research Symposium, May 9, 2014 at ASCO Conference Center in Alexandria, VA. Alexandria, VA...

2014-04-07 11:01:42

Given omega 6 fatty acid's reputation for promoting cancer — at least in animal studies — researchers are examining the role that antioxidants play in blocking the harmful effects of this culprit, found in many cooking oils. After all, antioxidants are supposed to prevent DNA damage. But employing antioxidants could backfire, say researchers at Georgetown Lombardi Comprehensive Cancer Center. In their study, being reported at the AACR Annual Meeting 2015, researchers found that vitamin...

2014-04-07 08:30:29

- Data Advances microRNA Oncology Portfolio - LA JOLLA, Calif., April 7, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that three abstracts will be presented in poster presentation sessions during the American Association for Cancer Research (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego, CA. An oral presentation will also be...

2014-03-26 16:15:10

In a series of studies involving 140 American men and women with liver tumors, researchers at Johns Hopkins have used specialized 3-D MRI scans to precisely measure living and dying tumor tissue to quickly show whether highly toxic chemotherapy – delivered directly through a tumor's blood supply – is working. The investigators say their findings, to be presented March 22-27 in San Diego at the annual meeting of the Society of Interventional Radiology, are the first "proof of principle"...

2014-03-20 08:30:23

WOONSOCKET, R.I., March 20, 2014 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) has filed additional U.S. and international patent applications covering MCT-485 and its composition of matter, biological targets, mechanism of action, and methods and formulations for therapeutic use. MCT-485 is a very small noncoding double stranded RNA (dsRNA) molecule which has demonstrated a unique cytotoxic, oncolytic, and immune stimulating activity in in vitro models of...

2014-03-17 08:28:41

CF102 has Orphan Drug Designation from U.S. FDA PETACH TIKVA, Israel, March 17, 2014 /PRNewswire/ -- Can-Fite BioPharma (TASE: CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that a Phase II study protocol for the treatment of advanced liver cancer with its CF102 has been approved by the Institutional Review Board (IRB) in Israel. The company plans to conduct...